# Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia

> **NCT07549464** · PHASE1 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 12 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** PLM-102

## Key facts

- **NCT ID:** NCT07549464
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2029-06-01
- **Final completion:** 2031-06-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07549464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07549464, "Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07549464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*